Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Miller

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 28, 2011
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tabletM R McClung, P D Miller, J P Brown, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 30, 2008
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient dataA Cranney, G A Wells, E Yetisir, et al.
The American Journal of Medicine|November 3, 2015
Vertebral Fractures: Clinical Importance and ManagementD L Kendler, D C Bauer, K S Davison, et al.
JAMA|October 20, 1999
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupS T Harris, N B Watts, H K Genant, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|October 3, 2002
Standards and guidelines for performing central dual X-ray densitometry from the Canadian panel of International Society for Clinical DensitometryA A Khan, J Brown, K Faulkner, et al.
The American Journal of Medicine|January 16, 1998
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatmentP D Miller, N B Watts, A A Licata, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 13, 2015
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 yearsS Ferrari, J D Adachi, K Lippuner, et al.
Annals of the Rheumatic Diseases|December 13, 2005
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyJ-Y Reginster, S Adami, P Lakatos, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 16, 2019
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over groupJ P Bilezikian, C J F Lin, J P Brown, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 28, 2011
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tabletM R McClung, P D Miller, J P Brown, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 30, 2008
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient dataA Cranney, G A Wells, E Yetisir, et al.
The American Journal of Medicine|November 3, 2015
Vertebral Fractures: Clinical Importance and ManagementD L Kendler, D C Bauer, K S Davison, et al.
JAMA|October 20, 1999
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupS T Harris, N B Watts, H K Genant, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|October 3, 2002
Standards and guidelines for performing central dual X-ray densitometry from the Canadian panel of International Society for Clinical DensitometryA A Khan, J Brown, K Faulkner, et al.
The American Journal of Medicine|January 16, 1998
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatmentP D Miller, N B Watts, A A Licata, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 13, 2015
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 yearsS Ferrari, J D Adachi, K Lippuner, et al.
Annals of the Rheumatic Diseases|December 13, 2005
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyJ-Y Reginster, S Adami, P Lakatos, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 16, 2019
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over groupJ P Bilezikian, C J F Lin, J P Brown, et al.
Pageof 18